Amarantus Enters Into Wolfram’s Research Collaboration With Washington University School of Medicine

ST. LOUIS, SAN FRANCISCO and GENEVA, Jun 20, 2014 (GLOBE NEWSWIRE via COMTEX) Amarantus Bioscience Holdings, Inc., (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has entered into a research collaboration with the Washington University School of Medicine in St. Louis to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals. Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine, will be leading the research. The project initially focuses on evaluating MANF treatment efficacy in retinal cells that are produced from induced pluripotent stem cells, which were derived from Wolfram s patients. Dr. Urano has developed his models of retinal damage with funding from the Jack and JT Snow Foundation. I am so pleased and thrilled that Amarantus has d
http://bit.ly/1npedjR